甘李药业股份有限公司 关于变更保荐代表人的公告

Core Viewpoint - The company has announced a change in the designated sponsor representatives for its initial public offering (IPO) project on the Shanghai Stock Exchange, with a new representative appointed to ensure ongoing supervision [1][2]. Group 1: Change in Sponsorship - The company received a notice from CITIC Securities regarding the change of sponsor representatives for its IPO project [1]. - Wang Qi, the original sponsor representative, will no longer be responsible for the ongoing supervision due to a job change, effective February 2026 [1]. - Shao Caijie has been appointed as the new sponsor representative to replace Wang Qi, alongside Zhao Luyin, to continue the supervision until the obligations end as per regulations [1]. Group 2: Acknowledgment of Contributions - The company's board expressed gratitude for Wang Qi's contributions during the supervision period [2]. Group 3: New Sponsor Representative Profile - Shao Caijie holds a master's degree and is currently the director of the Investment Banking Management Committee at CITIC Securities [3]. - She has been involved in several significant projects, including the IPOs of United Imaging Healthcare and Kemei Diagnostics, and has a good compliance record in her sponsorship activities [3].